#5 - Cellectis (NASDAQ:CLLS)
Cellectis S.A. (NASDAQ: CLLS) is a clinical-stage gene editing company that is tightly focused on oncology treatments. The company's pipeline is based on its proprietary gene-editing technology named TALEN. The goal is to identify gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells.
Although CLLS stock is down 32% for the year, it’s up nearly 2% in the 30 days ending August 6, 2024. Much of that is due to two orphan drug designations from the FDA. The first came on July 25 for its UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) treatment. The second came on August 1, when it received the same approval for its CLLS52 candidate.
But investors need to remember that receiving orphan drug designation is not comparable with receiving approval. Nor does it mean that any of these drugs will make it through the process. That means profitability is years away. Nevertheless, the Cellectis analyst forecasts on MarketBeat give the stock a Buy rating with an $8 price target. That’s 288% higher than its price on August 6, 2024.
About Cellectis
Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.
Read More - Current Price
- $2.05
- Consensus Rating
- Buy
- Ratings Breakdown
- 3 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $7.00 (241.5% Upside)
